Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education and Tianjin, College of Biotechnology, Tianjin University of Science and Technology, P.R. China300457.
Food Funct. 2019 Feb 20;10(2):1132-1145. doi: 10.1039/c8fo02301h.
Multiple articles have confirmed that an imbalance of the intestinal microbiota is closely related to aberrant immune responses of the intestines and to the pathogenesis of inflammatory bowel diseases (IBDs). Probiotic strains have been identified for the treatment and prevention of IBDs. The aim of this study was to screen a new probiotic strain with anti-inflammatory activity and investigate the potential mechanisms underlying its activity. We identified a new probiotic strain, L. lactis ML2018, that has anti-inflammatory properties and was isolated from traditional fermented food. In an in vitro experiment, L. lactis ML2018 prevented the release of nitric oxide (NO) and the production of inflammatory factors induced by lipopolysaccharides (LPS) in RAW264.7 cells. The in vivo anti-inflammatory effects of L. lactis ML2018 were evaluated using a dextran sulfate sodium (DSS)-induced animal model of colitis. Oral administration of L. lactis ML2018 significantly ameliorated colitis induced by DSS, which included preventing a decrease in body weight, shortening of the colon length and apoptosis of epithelial cells. L. lactis ML2018 could inhibit DSS-induced intestinal inflammation by preventing the overproduction of proinflammatory factors, suppressing the infiltration of macrophages, controlling the fibrosis, improving the integrity of the intestinal epithelial barrier and upregulating the concentrations of short-chain fatty acids (SCFAs). Moreover, L. lactis ML2018 could prevent inflammation by inhibiting the activation of the NF-κB and MAPK signaling pathways. These data suggest that L. lactis ML2018 could have therapeutic potential for treating IBDs.
多篇文章证实，肠道微生物群失衡与肠道异常免疫反应和炎症性肠病 (IBD) 的发病机制密切相关。已经确定了一些益生菌菌株可用于治疗和预防 IBD。本研究旨在筛选具有抗炎活性的新型益生菌菌株，并探讨其活性的潜在机制。我们从传统发酵食品中分离出一种具有抗炎特性的新型益生菌菌株乳杆菌 ML2018。在体外实验中，乳杆菌 ML2018 可防止 RAW264.7 细胞中脂多糖 (LPS) 诱导的一氧化氮 (NO) 释放和炎症因子的产生。使用葡聚糖硫酸钠 (DSS) 诱导的结肠炎动物模型评估了乳杆菌 ML2018 的体内抗炎作用。乳杆菌 ML2018 的口服给药可显著改善 DSS 诱导的结肠炎，包括防止体重下降、结肠长度缩短和上皮细胞凋亡。乳杆菌 ML2018 通过防止促炎因子的过度产生、抑制巨噬细胞浸润、控制纤维化、改善肠上皮屏障的完整性和上调短链脂肪酸 (SCFA) 的浓度来抑制 DSS 诱导的肠道炎症。此外，乳杆菌 ML2018 可通过抑制 NF-κB 和 MAPK 信号通路的激活来预防炎症。这些数据表明，乳杆菌 ML2018 可能具有治疗 IBD 的潜力。
